Your browser doesn't support javascript.
loading
Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.
Sezer, Orhan; Beksac, Meral; Hajek, Roman; Sucak, Gülsan; Cagirgan, Seckin; Linkesch, Werner; Meltem Akay, Olga; Gülbas, Zafer; Nahi, Hareth; Plesner, Torben; Snowden, John A; Timuragaoglu, Aysen; Dechow, Tobias; Lang, Alois; Tuglular, Tülin; Drach, Johannes; Armbrecht, Gabriele; Potamianou, Anna; Couturier, Catherine; Olie, Robert A; Feys, Caroline; Allietta, Nathalie; Terpos, Evangelos.
Afiliación
  • Sezer O; Department of Haematology, Oncology, and Bone Marrow Transplantation, Universitaetsklinikum Eppendorf, Hamburg, Germany.
  • Beksac M; Department of Medicine, Ankara University, Ankara, Turkey.
  • Hajek R; Department of Haemato-oncology, University Hospital Ostrava, Ostrava, Czech Republic.
  • Sucak G; Faculty of Medicine, University Ostrava, Ostrava, Czech Republic.
  • Cagirgan S; Department of Haematology, Faculty of Medicine, Gazi University, Ankara, Turkey.
  • Linkesch W; Department of Haematology, Izmir Medical Park Private Hospital, Izmir, Turkey.
  • Meltem Akay O; Department of Haematology, Medical University Clinic, Medical University of Graz, Graz, Austria.
  • Gülbas Z; Department of Haematology, Eskisehir Osmangazi University, Eskisehir, Turkey.
  • Nahi H; Department of Haematology, Eskisehir Osmangazi University, Eskisehir, Turkey.
  • Plesner T; Oncologic Sciences, Anadolu Health Centre, Kocaeli, Turkey.
  • Snowden JA; Department of Haematology, Karolinska University Hospital, Stockholm, Sweden.
  • Timuragaoglu A; Department of Haematology, Vejle Hospital, Vejle, Denmark.
  • Dechow T; IRS/University of Southern Denmark, Vejle, Denmark.
  • Lang A; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Tuglular T; Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
  • Drach J; Department of Haematology, Akdeniz University, Antalya, Turkey.
  • Armbrecht G; III. Medical Dept., Klinikum Rechts der Isar, Technical University Munich, Munich, Germany.
  • Potamianou A; Department of Haematology and Oncology, LandesKrankenhaus, Feldkirch, Austria.
  • Couturier C; Department of Internal Medicine, Marmara University, Istanbul, Turkey.
  • Olie RA; Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
  • Feys C; Department of Radiology, Centre for Muscle and Bone Research, Charité - Campus Benjamin Franklin, Berlin, Germany.
  • Allietta N; Janssen-Cilag Pharmaceutical SACI, Athens, Greece.
  • Terpos E; Janssen-Cilag, Issy-les-Moulineaux, France.
Br J Haematol ; 178(1): 61-71, 2017 07.
Article en En | MEDLINE | ID: mdl-28382618
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteólisis / Quimioterapia de Consolidación / Bortezomib / Mieloma Múltiple / Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Año: 2017 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteólisis / Quimioterapia de Consolidación / Bortezomib / Mieloma Múltiple / Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Año: 2017 Tipo del documento: Article País de afiliación: Alemania